Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Summary

The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the VRX-RET-E22-301 double-blind study. The efficacy of long-term treatment with retigabine and patient quality of life will also be assessed.

Timeline

Start

2006-05-01

Primary completion

2016-11-30

Completion

2017-03-15

Drugs

Indications